Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Ophthalmology

Search Medical Condition
Please enter condition
Please choose location from dropdown

Posterior Uveitis Clinical Trials

A listing of Posterior Uveitis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (10) clinical trials

Ozurdex in Patients With Non-infectious Uveitis Affecting the Posterior Segment of the Eye

This observational study will evaluate the safety, efficacy, characteristics of patients, characteristics of physicians and quality of life in patients who are prescribed OZURDEX as treatment for non-infectious uveitis of the posterior segment of the eye in France.

Phase N/A

Study of the Effectiveness of Ozurdex for the Control of Uveitis

Objectives: This is a single arm study evaluating whether or not the dexamethasone pellet (Ozurdex, Allergan, Irvine, CA) can replace oral corticosteroid (e.g. prednisone) in the treatment of active sight-threatening, noninfectious intermediate or posterior uveitis in which immunosuppressive drug therapy is indicated. Background: Intermediate and posterior uveitis are thought to ...

Phase

Evaluation of EYS606 in Patients With Non-infectious Posterior Intermediate or Panuveitis

The maximum study duration per patient is 27 Weeks (including an up to 3 week screening period + 24 weeks follow-up after treatment). The study is conducted in 2 parts. Part 1 is a dose escalation phase which will investigate 3 pEYS606 doses levels (lower, intermediate and higher dose) over ...

Phase

Efficacy and Safety of H.P. ACTHAR GEL in Adults With Retinal Vasculitis

The purpose of this study is to evaluate the short- and long-term efficacy and safety of Acthar for the treatment of adults with non-infectious retinal vasculitis.

Phase

Intravitreal Sirolimus as Therapeutic Approach to Uveitis

Uveitis is a condition in which certain parts of your eye become inflamed. The inflammation is usually recurrent. If the inflammation is not treated adequately, permanent damage to the eye and to the vision may occur. The inflammation can be caused by infectious or non infectious causes. The current research ...

Phase

Outcome of Different IOLs in Patients With and Without Uveitis

Cataract, is a clouding of the lens in the eye gradually leading to reduction of the visual acuity. In most cases it can be managed with surgery, removing the own lens and replacing it with an artificial lens, intraocular lens (IOL). These lenses are made in different materials with different ...

Phase N/A

Quality of Life and Visual Function in Uveitis Patients

The National Eye Institute Visual Functioning Questionnaire, version August 2000 (NEI VFQ-25) and the Medical Outcomes Study (MOS) 36 Item Short Form Health Survey Instrument (SF-36) (RAND 36-Item Health Survey 1.0 Questionnaire) will be administered by a trained interviewer. Socio-demographic and clinical data will be collected for additional QOL parameter.

Phase

HUMIRA Long-term Treatment in Patients With Non-infectious Intermediate- Posterior- or Pan-uveitis

This study evaluates the long- term safety and effectiveness of adalimumab in participants with non-infectious intermediate-, posterior-, or pan-uveitis in daily practice in Japan.

Phase N/A

Impact of Humira Therapy on Ocular Inflammation Selected Health Care Resource Utilization and Patient Reported Outcomes in Patients With Active Non-infectious Intermediate Posterior and Panuveitis in Routine Clinical Practice

This study aims at evaluating real life effectiveness of originator adalimumab (Humira) participants with active non-infectious intermediate, posterior and panuveitis (NIIPPU) despite high-dose corticosteroid therapy; including effect on ocular inflammation, health-related quality of life, health resource utilization, work ability and medication burden, as well as describe the characteristics of NIIPPU ...

Phase N/A

Post-marketing Surveillance Study of Adalimumab (Humira ) for Non-infectious Intermediate Posterior or Panuveitis Patients

The objective of this study is to evaluate the safety and effectiveness of Humira (Adalimumab) for the treatment of non-infectious intermediate, posterior, or panuveitis patients under a routine treatment practice.

Phase N/A